Janssen is exploring innovative applications of our HIV medicines to improve treatment and prevention outcomes in hard-to-reach areas by finding ways to reduce the frequency of dosing. We’re also working in collaboration with non-profit product development partners to research new pathways to prevent HIV infection through injectable formulations and microbicidal rings.

Janssen collaborated with the International Partnership for Microbicides (IPM), a nonprofit organization dedicated to developing new HIV prevention technologies for women, to develop sexual and reproductive health products containing antiretroviral drugs to evaluate the prevention of sexual transmission of HIV. Read more about this partnership here.